annual CFF:
$133.16M-$101.12M(-43.16%)Summary
- As of today (August 22, 2025), ELVN annual cash flow from financing activities is $133.16 million, with the most recent change of -$101.12 million (-43.16%) on December 31, 2024.
- During the last 3 years, ELVN annual CFF has risen by +$134.18 million (+13206.79%).
- ELVN annual CFF is now -43.16% below its all-time high of $234.29 million, reached on December 31, 2023.
Performance
ELVN Cash from financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFF:
$218.38M+$218.14M(+93223.93%)Summary
- As of today (August 22, 2025), ELVN quarterly cash flow from financing activities is $218.38 million, with the most recent change of +$218.14 million (+93223.93%) on June 30, 2025.
- Over the past year, ELVN quarterly CFF has increased by +$216.57 million (+11991.81%).
- ELVN quarterly CFF is now -8.03% below its all-time high of $237.44 million, reached on March 31, 2023.
Performance
ELVN quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
$259.70M+$216.57M(+502.15%)Summary
- As of today (August 22, 2025), ELVN TTM cash flow from financing activities is $259.70 million, with the most recent change of +$216.57 million (+502.15%) on June 30, 2025.
- Over the past year, ELVN TTM CFF has increased by +$167.96 million (+183.08%).
- ELVN TTM CFF is now at all-time high.
Performance
ELVN TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
ELVN Cash from financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -43.2% | +10000.0% | +183.1% |
| 3 y3 years | +10000.0% | +10000.0% | +447.9% |
| 5 y5 years | +205.6% | +2176.4% | +170.1% |
ELVN Cash from financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -43.2% | >+9999.0% | -8.0% | +7843.9% | at high | >+9999.0% |
| 5 y | 5-year | -43.2% | >+9999.0% | -8.0% | +7843.9% | at high | >+9999.0% |
| alltime | all time | -43.2% | >+9999.0% | -8.0% | +7843.9% | at high | >+9999.0% |
ELVN Cash from financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | $218.38M(>+9900.0%) | $259.70M(+502.1%) |
| Mar 2025 | - | $234.00K(-99.4%) | $43.13M(-67.6%) |
| Dec 2024 | $133.16M(-43.2%) | $39.97M(+3478.5%) | $133.16M(+42.8%) |
| Sep 2024 | - | $1.12M(-38.2%) | $93.28M(+1.7%) |
| Jun 2024 | - | $1.81M(-98.0%) | $91.74M(+5.3%) |
| Mar 2024 | - | $90.27M(>+9900.0%) | $87.11M(-62.8%) |
| Dec 2023 | $234.29M(<-9900.0%) | $90.00K(-121.2%) | $234.29M(+0.8%) |
| Sep 2023 | - | -$425.00K(-84.9%) | $232.38M(-0.3%) |
| Jun 2023 | - | -$2.82M(-101.2%) | $232.97M(-1.2%) |
| Mar 2023 | - | $237.44M(<-9900.0%) | $235.80M(<-9900.0%) |
| Dec 2022 | -$1.23M | -$1.81M(-1204.3%) | -$1.23M(-317.1%) |
| Sep 2022 | - | $164.00K(+3180.0%) | $568.00K(-98.8%) |
| Jun 2022 | - | $5000.00(-98.8%) | $47.40M(-3.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | $409.00K(-4190.0%) | $49.05M(-0.1%) |
| Dec 2021 | -$1.02M(-101.0%) | - | - |
| Dec 2021 | - | -$10.00K(-100.0%) | $49.10M(-1.2%) |
| Sep 2021 | - | $46.99M(+2730.8%) | $49.71M(+1642.9%) |
| Jun 2021 | - | $1.66M(+260.9%) | $2.85M(-73.6%) |
| Mar 2021 | - | $460.00K(-22.9%) | $10.79M(-88.9%) |
| Dec 2020 | $96.88M(+122.3%) | $597.00K(+342.2%) | $96.88M(+0.6%) |
| Sep 2020 | - | $135.00K(-98.6%) | $96.28M(+0.1%) |
| Jun 2020 | - | $9.59M(-88.9%) | $96.15M(+11.1%) |
| Mar 2020 | - | $86.56M | $86.56M |
| Dec 2019 | $43.58M(+571.7%) | - | - |
| Dec 2018 | $6.49M(-41.0%) | - | - |
| Dec 2017 | $11.00M | - | - |
FAQ
- What is Enliven Therapeutics, Inc. annual cash flow from financing activities?
- What is the all time high annual CFF for Enliven Therapeutics, Inc.?
- What is Enliven Therapeutics, Inc. annual CFF year-on-year change?
- What is Enliven Therapeutics, Inc. quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Enliven Therapeutics, Inc.?
- What is Enliven Therapeutics, Inc. quarterly CFF year-on-year change?
- What is Enliven Therapeutics, Inc. TTM cash flow from financing activities?
- What is the all time high TTM CFF for Enliven Therapeutics, Inc.?
- What is Enliven Therapeutics, Inc. TTM CFF year-on-year change?
What is Enliven Therapeutics, Inc. annual cash flow from financing activities?
The current annual CFF of ELVN is $133.16M
What is the all time high annual CFF for Enliven Therapeutics, Inc.?
Enliven Therapeutics, Inc. all-time high annual cash flow from financing activities is $234.29M
What is Enliven Therapeutics, Inc. annual CFF year-on-year change?
Over the past year, ELVN annual cash flow from financing activities has changed by -$101.12M (-43.16%)
What is Enliven Therapeutics, Inc. quarterly cash flow from financing activities?
The current quarterly CFF of ELVN is $218.38M
What is the all time high quarterly CFF for Enliven Therapeutics, Inc.?
Enliven Therapeutics, Inc. all-time high quarterly cash flow from financing activities is $237.44M
What is Enliven Therapeutics, Inc. quarterly CFF year-on-year change?
Over the past year, ELVN quarterly cash flow from financing activities has changed by +$216.57M (+11991.81%)
What is Enliven Therapeutics, Inc. TTM cash flow from financing activities?
The current TTM CFF of ELVN is $259.70M
What is the all time high TTM CFF for Enliven Therapeutics, Inc.?
Enliven Therapeutics, Inc. all-time high TTM cash flow from financing activities is $259.70M
What is Enliven Therapeutics, Inc. TTM CFF year-on-year change?
Over the past year, ELVN TTM cash flow from financing activities has changed by +$167.96M (+183.08%)